💊 Foundayo: The Once-Daily GLP-1 Pill

On April 1, 2026, the FDA approved Foundayo (orforglipron) for weight management — the first non-peptide oral GLP-1. That "non-peptide" part is the whole story. Rybelsus, the only other GLP-1 pill, is a peptide: it degrades in the stomach unless taken on an empty stomach with a strict sip of water and a 30-minute wait before eating. Foundayo is a small molecule. It survives the gut on its own terms — no food or water timing rules, no refrigeration, room-temperature storage.

The ATTAIN-1 Phase 3 numbers: 12.4% average weight loss at the 36 mg dose over 72 weeks, versus 0.9% on placebo. Roughly six in ten participants lost at least 10% of their body weight. That puts a once-daily pill within striking distance of the injectables' headline results, without a needle.

📊 Weight loss comparison

The ACHIEVE program is where the newest readouts live — and these are company-presented, via trade press. ACHIEVE-4 reported cardiovascular protection signals alongside weight loss and glycemic control in type 2 diabetes. ACHIEVE-3 went head-to-head against oral semaglutide and beat it on blood-sugar endpoints. The cardio angle matters: if the protection signal holds in a dedicated outcomes trial, Foundayo stops being just a convenience play and becomes a first-line metabolic drug.

The access story may be bigger than the trial story. Foundayo's pill formulation is covered under Medicare's Bridge pilot at a flat $50/month copay — no injection training, no cold chain, no prior-auth maze through individual Part D plans. For the 20 million seniors who could be eligible, a once-daily pill at $50 a month changes the math completely.

What to watch: real-world uptake against the injectables, whether commercial payers match the Bridge pricing, and how fast Lilly can scale small-molecule manufacturing — the one bottleneck peptides never had to solve.